Evotec has entered into a collaboration with Active Biotech to screen for small molecule modulators to identify a priority biological target, selected by Active Biotech, involved in immune disorders and cancer.
Under the agreement Evotec will use its expertise and technologies in assay development, high throughput screening (HTS) and surface plasmon resonance (SPR) screening for the identification and validation of novel targets.
To maximise the probability of finding high-quality medicinal chemistry starting points, Evotec will screen its Lead Discovery Library, a small molecule collection designed for diversity, novelty and quality.
Active Biotech director of development Dorthe da Graça Thrige said that Evotec's Lead Discovery Library will enable the company to generate high-quality hits, ensuring a smooth transition to medicinal chemistry activities.
"Importantly, the hits identified in the HTS will complement the ongoing lead optimisation of compounds identified in-house," Thrige said.
No financial details have been disclosed.
